| Theme | Current Status of Uprising Strategy for Esophageal Cancer Treatment | |
|---|---|---|
| Title | Current Status of Chemoradiotherapy for Esophageal Carcinoma | |
| Publish Date | 2011/09 | |
| Author | Katsuhiko Higuchi | Department of Gastroenterology, Kitasato University School of Medicine |
| Author | Chikatoshi Katada | Department of Gastroenterology, Kitasato University School of Medicine |
| Author | Tohru Sasaki | Department of Gastroenterology, Kitasato University School of Medicine |
| Author | Mizutomo Azuma | Department of Gastroenterology, Kitasato University School of Medicine |
| Author | Kenji Ishido | Department of Gastroenterology, Kitasato University School of Medicine |
| Author | SatoshiTanabe | Department of Gastroenterology, Kitasato University School of Medicine |
| Author | Wasaburo Koizumi | Department of Gastroenterology, Kitasato University School of Medicine |
| [ Summary ] | In Japan, squamous cell carcinoma accounts for 93 % of all esophageal carcinomas. Because squamous cell carcinoma is generally sensitive to radiation, definitive chemoradiotherapy, which allows the esophagus to be preserved, is considered to be useful therapeutically. Cisplatin, 5-fluorouracil, with concurrent radiation with 50.4 Gy is employed as the standard treatment, based on the results of randomized clinical trials (RTOG 85-01 and RTOG 94-05/INT 0123) performed in North America. Similar regimens have been introduced for patients with stage II/III in Japan. In patients who have T4 tumors and/or M1 lymph-node metastasis, chemoradiotherapy with cisplatin, 5-fluorouracil and concurrent radiation with 60 Gy is considered to be the standard treatment. However, docetaxel, cisplatin, and 5-fluorouracil plus concurrent radiotherapy is also being investigated. | |